Abstract
Cefotetan (CTT, YM 09330), a new cephamycin derivative, was investigated on its serum level, bile concentration, clinical effectiveness and side effects.
Following one shot intravenous injection of each 1 g cefotetan in 2 patients after cholecystectomy, the mean serum level showed a peak of 145μg/ml at 30 min, and lasted more than 32.3μg/ml for 6 hours.
The bile concentrations were not similar between 2 cases. In one case its peak was found at 2 hours, but in another at one hour, and their concentrations were 408 μg/ml and 171μg/ml respectively.
Cefotetan was given to 44 patients with various surgical infections, but 4 patients were excluded because Pseudomonasm isolated from their wounds. The results obtained were “excellent” in 14, “good” in 16, “fair” in 3, “poor” in 7 and efficacy rate was 75.0%. Particularly satisfactory results were as follow: Excellent and good in 11 cases out of 12 patients with peritonitis, 4 out of 8 patients with postoperative intraperitoneal infection, 4 out of 5 patients with postoperative wound infection, 4 out of 5 patients with abscess, 3 out of 3 patients with binary tract infections, 2 out of 4 patients with respiratory tract infections and 2 out of 3 patients with sepsis.
Side effects were not observed except elevated values of GOT, GPT and Al-p in 3 cases, BUN in 2 cases and agranulocytosis in one case respectively.
